The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.
about
Flexible Cyclic Ethers/Polyethers as Novel P2-Ligands for HIV-1 Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies †Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies ∞Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease InhibitorsIncreasing clinical virulence in two decades of the Italian HIV epidemicTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadDoravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual.Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.Minority variants of drug-resistant HIV.Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund ProjectHIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, IndonesiaTransmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialClade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in EthiopiaDetection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients.Prevalence of and viral outcomes associated with primary HIV-1 drug resistanceBaseline clinical characteristics, antiretroviral therapy use, and viral load suppression among HIV-positive young men of color who have sex with men.Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.Transmission networks of drug resistance acquired in primary/early stage HIV infection.Clinical management of acute HIV infection: best practice remains unknown.Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan.Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.Identification of Novel Resistance-Related Polymorphisms in HIV-1 Subtype C RT Connection and RNase H Domains from Patients Under Virological Failure in Brazil.Clinical, virological and phylogenetic characterization of a multiresistant HIV-1 strain outbreak in naive patients in southern Spain.Resistance to protease inhibitors in a model of HIV-1 infection with impulsive drug effects.Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecksDemonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007.A novel methodology for large-scale phylogeny partition.An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors.HIV-1 transmission networks across Cyprus (2010-2012).Monitoring HIV drug resistance in treatment-naive individuals: molecular indicators, epidemiology and clinical implicationsTransmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings
P2860
Q27652070-37415B00-2C93-42DF-BDA0-4BB2665DCA17Q27655631-AF48A234-9E41-4C51-B63F-308BF54FBB7EQ27664394-AE262C30-8D26-45C0-BE20-43DC3A788368Q28475522-2871B35A-3377-4450-870A-4DA13819ECC2Q28478656-BF491699-A0E5-45CD-8404-6B8B2DEEF9C0Q30373063-1AEB55AA-4E4F-4D1D-A82B-C6F1B69AB9B2Q33354082-02FD1787-DD53-493C-ACE9-A0BEEF525278Q33870886-DE64C589-1700-4E72-A9BA-B16B10069096Q34047780-92D30C24-B43F-4E37-8580-EB975A8ACD59Q34507768-E9AC72F2-D101-40D8-BC25-F0BE025BC638Q34553890-81954E84-42CB-49EF-A6C7-EEDB3018192AQ35107698-CDFA4B02-C768-427F-8447-58D1C2A545FEQ35114874-4906DA04-9BB8-4408-B61F-680CBD3C036CQ35124860-4A30A22B-C099-4DB4-A4AB-EDF20AFDB47DQ35127254-C9CED647-1A27-43AF-B731-CD38B92878DCQ35140450-ADFF2C7B-96E9-4858-A108-40C8E5F8E017Q35231732-DD64F13A-D5D3-48A7-B9B0-0709CA77C570Q35913936-B9DB1D81-0F3D-4957-A4B9-9F7B507ED6CBQ36274049-09A2D6E5-CE98-4D63-B7C4-0D284A58FEF9Q36279238-DFCDF4A2-B68A-4ECE-90E0-18E247980F77Q36291581-E923522E-840D-48CE-9A91-BD4B3D4D0633Q36730278-A9367173-790A-4541-9C80-EAF814FF4729Q36798007-4A3955F6-C063-49E1-B9E6-2364D1E82195Q37115372-35FD030E-4BD7-4580-BE01-574E6C6FC426Q37789343-147A18A0-F343-4C8A-ACEE-D2FEEE7DE401Q38405467-1FBC221E-B3BF-4B24-8B40-EBAF08753911Q39080507-9E2F3837-669E-4E96-B7EB-7C95D9E511CAQ40440258-0071A3DD-E727-46C8-A855-46A193F761F5Q40944825-44BDB905-BA14-4984-9F53-68573FB63B37Q42257557-E1BE90A8-C5F8-4D08-B098-F54F4315F847Q42577298-4E9AC557-597A-47BE-A4CF-F43168656A26Q43173413-7986CE98-90CC-437B-9E29-EBDF08D6E02EQ43239908-856F400E-7424-4990-9B91-B5472E6C403FQ45822128-09395F10-5AA3-4D80-94C8-30E08E645E33Q50097601-2C9881AC-0979-4D2B-BC18-E69428C98382Q54230313-440D5886-712C-411A-9BA7-2FA4D9EDD060Q57708766-C3807CDD-5D23-44E4-9548-2C4EFEBDC488Q57880269-7D3E96A0-368C-4584-99C2-61BC54FE9ABB
P2860
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The impact of transmitted drug ...... esponse to first-line therapy.
@en
type
label
The impact of transmitted drug ...... esponse to first-line therapy.
@en
prefLabel
The impact of transmitted drug ...... esponse to first-line therapy.
@en
P2093
P50
P1433
P1476
The impact of transmitted drug ...... esponse to first-line therapy.
@en
P2093
Bernard Masquelier
CASCADE Virology Collaboration
Carmen de Mendoza
Claudia Balotta
Claudia Kücherer
Claus Nielsen
Court Pedersen
Gabriele Poggensee
Kholoud Porter
P356
10.1097/01.AIDS.0000196172.35056.B7
P407
P577
2006-01-01T00:00:00Z